久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

chi-med 和黃中國醫(yī)藥科技  


Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China. Chi-Med is a subsidiary of Hutchison Whampoa Ltd. ("HWL"), an international corporation listed on the Main Board of the Hong Kong Stock Exchange which had an annual turnover of approximately US$50 billion in 2011 and over a quarter million employees in 53 countries worldwide as at 31 December 2011.
Chi-Med focuses on researching, developing, manufacturing and selling pharmaceuticals, and health oriented consumer products primarily in the China market. Chi-Med was established in 2000 as a wholly-owned subsidiary of HWL.
Chi-Med operates three core divisions:
China Healthcare Division - Our China Healthcare Division is an established, stable, and diversified China pharmaceuticals operation with exciting growth prospects based on its market leading products and the rapid expansion of the pharmaceutical industry in China. This is being driven by the increase in the government spending on national healthcare, as well as the upgrading of living standards, translating into an increasingly strong source of profit and cash for the Group.
Drug R&D Division - Over the past ten years, we have invested approximately $100 million in establishing China's leading end-to-end oncology and immunology drug R&D operation. We are creating highly innovative therapies for launch in the fast growth China market and the global market.
Consumer Products Division - Our Consumer Products Division is an extension of our China operation which enables Chi-Med to capture part of the growing consumer trend towards healthy living and to capitalise on the considerable consumer products synergies with the broader HWL group. We aim to build a profitable scale business over the coming five years behind a portfolio of relevant and unique health-related consumer products.